Kılıçkap, SaadettinDemirci, UmutBuğdaycı, FatmaTural, DenizKorkmaz, TanerPaydaş, SemraYılmaz, CoşkunTuna, HandeSezer, AhmetYeşil Çinkir, HavvaErman, MünireEralp, YeşimÇabuk, DevrimIşıkdoğan, AbdurrahmanDemirkazık, AhmetKaraoğlu, AzizYazılıtaş, DoğanÇay Şenler, FilizYumuk, Perran FuldenCoşkun, HaticeYıldız, İbrahimÖztop, İlhanBeypınar, İsmailAydın, KübraKaplan, M.Meydan, NezihÖlmez, Ömer FatihSeber, SamileArslan, ÇağatayŞendur, Mehmet Ali NahitÇiçin, İrfan2019-12-252019-12-252019Kılıçkap, S., Demirci, U., Buğdaycı, F., Tural, D., Korkmaz, T., Paydaş, S. ... Çiçin, İ. (2019). Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey. Journal of Thoracic Oncology içinde (S558-S559. ss.). Elsevier Science. https://doi.org/10.1016/j.jtho.2019.08.11661556-08641556-1380https://doi.org/10.1016/j.jtho.2019.08.1166https://hdl.handle.net/20.500.12511/4670Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK inhibitor. The aim of this study is to evaluate the efficacy and safety of lorlatinib in an Expanded Access Program (EAP) in Turkey. Method: The EAP was open-label, multicenter, and single-arm. Patients were eligible to receive lorlatinib (100 mg po/day) if they had advanced stage ALK-or ROS1-positive NSCLC and had progressed on crizotinib and/or second generation ALK inhibitors such as ceritinib or alectinib. The primary endpoint was PFS with lorlatinib. Secondary endpoints were objective response rate, overall survival, and safety.eninfo:eu-repo/semantics/openAccessALK PositiveROS1 PositiveLorlatinibAdvanced Stage Lung CancerConference Object1410S558S55910.1016/j.jtho.2019.08.1166Q1